



PicoWay®

Summary of 58 Peer-Reviewed Articles

June 2025

FDA Indications for Use: 510(k) Number K220853

The PicoWay laser system is indicated for the following at the specified wavelength:

532 nm: Removal of tattoos for Fitzpatrick skin types I-III to treat the following tattoo colors: red, yellow and orange.

730 nm: Removal of tattoos for Fitzpatrick skin types II-IV to treat the following tattoo colors: green and blue.

785 nm: Removal of tattoos for Fitzpatrick skin types II-IV to treat the following tattoo colors: green and blue.

1064 nm: Removal of tattoos for all skin types (Fitzpatrick I-VI) to treat the following tattoo colors: black, brown, green, blue and purple.

The PicoWay laser system is also indicated for benign pigmented lesions removal for Fitzpatrick Skin Types I-IV.

The Resolve handpiece (1064 nm) is also indicated for the treatment of acne scars in Fitzpatrick Skin Types II-V and for treatment of Melasma for Fitzpatrick Skin Types I-IV.

The Resolve handpieces (532 nm HE, 532 nm, 1064 nm) are also indicated for treatment of wrinkles in Fitzpatrick Skin Types I-IV.

The Resolve Fusion handpiece (532 nm) is indicated for the treatment of benign pigmented lesions in Fitzpatrick Skin Types I-IV.

FDA Indications for Use: 510(k) Number K220853

The PicoWay laser system is indicated for the following at the specified wavelengths:

532 nm:

- Treatment of Melasma for Fitzpatrick Skin Types I-IV.
- Treatment of café au lait macules (CALMs) for Fitzpatrick Skin Types I-IV.
- Treatment of Lentigines for Fitzpatrick Skin Types I-IV.

730 nm:

- Treatment of Lentigines for Fitzpatrick Skin Types I-IV.

1064 nm:

- Treatment of Melasma for Fitzpatrick Skin Types I-IV.
- Treatment of Nevus of Ota for Fitzpatrick Skin Types III-IV.

Mottled hyperpigmentation caused by mesotherapy: successful treatment with a picosecond 1064 nm Nd:YAG laser

Zhou Z, Ge Y. J Cosmet Laser Ther. 2025 May 8:1-3.

*Resolve & Zoom 1064 nm HPs
Pigmentation*

CASE STUDY

- A 30-year-old female (Fitzpatrick Skin Type III) who developed persistent, mottled pigmentary macules all over the face after mesotherapy treatment received two monthly treatment sessions using the PicoWay 1064 nm laser with the following two-step approach:
 - Step 1: 1064 nm Zoom handpiece - spot size of 6 mm, a low fluence of 0.9 J/cm², 3-4 passes
 - Step 2: 1064 nm Resolve handpiece 6 x 6 mm, 0.7 mJ, 2-3 passes.
- The left cheek was treated at the first session and the forehead and both cheeks were treated at the second session.
- The end point was defined as moderate erythema in the treated areas.
- To enhance the inhibition of melanin production, oral tranexamic acid was continued (0.25 g twice daily) and topical arbutin cream was used once nightly after the first treatment.


RESULTS

- After two treatment sessions, considerable improvement in her pigmentary lesions was observed, with no exacerbation or other complications.

The 730 nm picosecond titanium sapphire laser for treatment of kratom-induced hyperpigmentation

Alhadyani AA, Samaan C, Munavalli GS. Lasers Surg Med. 2025 Jul;57(5):373-382.

*PicoWay 730 nm HP
Pigmentation*



CASE SERIES

- Two Caucasian patients (32-year-old male and a 42-year-old female) with diagnosed kratom-induced photo-distributed pigmentation as a result of taking OTC kratom supplements were treated with the PicoWay 730 nm laser.
- The male patient had confluent brown to gray pigmented patches affecting the face, neck and bilateral hands (the discoloration spared the submental region and knuckles), while the female patient had brown to gray pigmented patches involving the face, chest, and bilateral hands (sparing knuckles and jewelry areas).
- Both patients underwent a series of three treatments, spaced 4–6 weeks apart using spot size: 3 mm, and fluence of 1.0–1.8 J/cm², frequency: 4–5 Hz or fluence of 1.5–1.8 J/cm², frequency: 3–4 Hz.
- Treatment endpoint was immediate light to moderate pigment whitening of the treated areas, with or without edema.

RESULTS


- Both patients showed significant improvement in the appearance of pigmentation following treatment.
- No adverse effects or recurrence of the discoloration were observed during the follow-up period.

 Open Access <https://pmc.ncbi.nlm.nih.gov/articles/PMC11687291/>

Treatment of cosmetic eyeliner tattoo blow-out with 1064-nm Nd:YAG picosecond laser

Dick MK, Camacho-Hubbard I, Swali R, Friedman PM. Dermatol Surg. 2025 Mar 20.

*PicoWay 1064 nm HP
Tattoo Removal*




CASE STUDY

- A 69-year-old female with Fitzpatrick Skin Type III and moderate dermatochalasis presented to the clinic 6 months after undergoing black cosmetic eyeliner tattooing to her upper eyelids. The day after the procedure, the patient observed a striking spreading of pigment to the bilateral medial and lateral canthi, nasojugal grooves, and lower eyelids outside the area of initial tattoo placement.
- The patient received three PicoWay 1064 nm laser treatments at 4 to 6-week intervals. Treatment parameters included 1.6 - 2.5 J/cm², spot sizes of 2-3 mm (Zoom handpiece), with a single pass.
- Treatment endpoint was an immediate dermal whitening.

RESULTS

- The patient had near complete clearance of migrated pigment after treatments.
- The patient tolerated the treatment well without any adverse events.



Analysis of efficacy of picosecond laser treatment for nevus of Ota

Ma S, Zhu H, Chen J, et al. Lasers Med Sci. 2025 Feb 6;40(1):72.

*PicoWay 1064 nm HP
Nevus of Ota*

STUDY DETAILS

- A retrospective review of 212 patients (68 males, 144 females; mean age 18.59 ± 11.69 years; Fitzpatrick Skin Types III-IV) who were treated for nevus of Ota with the PicoWay 1064 nm laser.
- Patients received 1 to 11 treatment sessions (3 to 6 months apart). Treatment parameters included a single pass with spot sizes of 3–4 mm, fluence ranging from 2.8 to 4.0 J/cm², frequency of 3 Hz. Laser parameters were adjusted based on the lesion's location, color, age, tanning classification and immediate skin response.

RESULTS

- 80 cases (38%) achieved complete clearance, 42 (20%) excellent outcomes, 45 (21%) good outcomes, 37 (17%) fair outcomes, and 8 (4%) had minimal effect. Overall effective rate was 79%.
- Treatment efficacy was impacted by patient age and the number of treatment sessions.
- Early intervention and higher frequency of treatment sessions were associated with improved treatment outcomes.
- Two patients experienced temporary post-inflammatory effects, while three exhibited folliculitis.
- There were no reported cases of persistent erythema, scarring, or hypopigmentation.

Huang Y, Liu X, Zhang M, Lin T. Clin Cosmet Investig Dermatol. 2024 Dec 27;17:3027-3032.

*PicoWay 730 nm HP
Benign Pigmented Lesions*

STUDY DETAILS

- Twelve patients (10 females, 2 males; mean age of 31 years and Fitzpatrick Skin Types III-IV) were treated for their freckles using the PicoWay 730 nm laser.
- Patients underwent one laser treatment and were followed-up after 8 weeks. Treatment included mean energy fluence of 3.43 ± 0.78 J/cm² (range 1.8–4.0 J/cm², median 3.75 J/cm²) and spot sizes of 2–3 mm.
- At the eight-week follow-up, two independent physicians assessed the treatment efficacy using lesion clearance rate and global aesthetic improvement scale [GAIS: worsening (1) - significant improvement (5)].
- Ex vivo human foreskins were also treated using one pass with fluence of 3.75 J/cm² and analyzed using hematoxylin and eosin (H&E) staining.

RESULTS

- The average clearance rate as 74.46% and the mean GAIS as 4.13 ± 0.61 .
- One patient exhibited hyperpigmentation (8.33%), and another patient developed hypopigmentation (8.33%) by the 8-week follow-up visit.
- Ex vivo foreskins analysis showed a large number of uniform vacuoles (primarily with 20–40 μm diameter) in the epidermal basal layer and the dermal papillae, immediately after the treatment. The vacuoles were uniformly sized, indicating the relatively uniform laser energy distribution.

 **Open Access** <https://pmc.ncbi.nlm.nih.gov/articles/PMC11687291/>

Comparison of the efficacy and safety of a 730-nm picosecond titanium sapphire laser and a 1064-nm picosecond neodymium yttrium aluminum garnet laser for the treatment of acquired bilateral nevus of Ota-like macules: A split-face, evaluator-blinded, randomized, and controlled pilot trial

Chen W, Wang Z, Li Z, Yuan C, Zhang X, Li L, Yan Y, Wang B. J Cosmet Dermatol. 2024 Dec;23(12):3961-3967.

*PicoWay 730 nm & 1064 HPs
Benign Pigmented Lesions*



STUDY DETAILS

- Fifteen participants with acquired bilateral nevus of Ota-like macules were randomized to undergo a single session of either the PicoWay 730 or 1064 laser on one side of the face and the other laser type on the contralateral side.
- Energy level for each patient was based on treatment end points defined as immediate whitening followed by redness and edema for the 730-nm laser or delayed punctuate purpura for the 1064-nm laser.
- Efficacy and safety assessments were performed by blinded visual evaluations at baseline, 12 weeks, and 24 weeks posttreatment.

RESULTS

- Compared to baseline, the 730-nm laser-treated side showed better improvement than that of the 1064-nm laser-treated side at 24 weeks posttreatment (1.67 ± 1.047 vs. 0.87 ± 0.640 , $p = 0.027$).
- There were no significant differences in discomfort and participants' satisfaction between the two laser treatment types.

 Open Access <https://onlinelibrary.wiley.com/doi/10.1111/jocd.16511>



Efficacy of 785-nm picosecond titanium sapphire laser for treatment of brown nevus of Ota lesions in FST II-V: A retrospective analysis

Swali RN, Estupiñan B, Guo EL, Richmond H, Friedman PM. Dermatol Surg. 2024 Nov 1;50(11):1046-1049.

*PicoWay 785 nm HP
Benign Pigmented Lesions*

STUDY DETAILS

- Seventeen patients (Fitzpatrick Skin Types II-V, age ranging from 14 to 38 years) with brown nevus of Ota were treated using the PicoWay 785 nm laser.
- Patients received an average of 3.2 sessions at 2 to 3 month's intervals. Laser parameters included a fluence of 1.0 J/cm², spot size of 4 mm, 3 to 5 passes, and total pulse count ranging from 209 to 1,300. Patients were pretreated with compounded topical anesthetic (benzocaine 20%/lidocaine 6%/tetracaine 6%) for 30 to 60 minutes.
- The treatment endpoint was dermal edema.

RESULTS

- Visual analog scale scores demonstrated a mean clearance of 51% to 75%. Subgroup analysis revealed an average clinical improvement of 26% to 50% for patients receiving 1 to 3 treatments, while those receiving 4 or more treatments achieved an average clinical improvement of 51% to 75% (average VAS scores 1.85 and 3.42, respectively).
- No pigmentary alterations were noted.



Successful use of picosecond laser treatment for seborrheic keratosis in three Asian patients

Swallow MA, Elgash M, Kim SR, Suozzi KC. JAAD Case Rep. 2024 Apr 16;48:46-48.

*PicoWay 532 nm HP
Benign Pigmented Lesions*

STUDY DETAILS

- Three Asian patients (2 males, 1 female; age range 67-70 years; FST IV) were treated for seborrheic keratoses on the face with a 532-nm picosecond laser.
- Subjects received 3-5 treatments (fluence range 0.5-1.4 J/cm²; Spot size 3 or 4). Time between treatments was variable and ranged from 1 to 10 months depending on each patient's schedules. The treatment endpoint was a light white frost.

RESULTS

- There was marked improvement in the size, number, and color of the lesions following treatment.
- No post-inflammatory hyperpigmentation, hypopigmentation, significant swelling, or other adverse events were noted.

The 730 nm picosecond titanium sapphire laser for treatment of café-au-lait macules in all skin types

Fernandez JK, Guo EL, Richmond H, Friedman PM. *Lasers Surg Med.* 2024 Mar;56(3):257-262.

*PicoWay 730 nm HP
Benign Pigmented Lesions*

STUDY DETAILS

- A retrospective review of 14 patients (age range: 10 months–66 years, mean age: 27.4 years, Fitzpatrick skin types II–VI) treated for CALMs on the face (11) or body (3) with the 730 nm picosecond titanium sapphire laser.
- Treatment parameters included spot sizes ranging from 3 to 4 mm and fluences ranging from 0.7 to 1.8 J/cm². On average, patients received 4.3 treatments, with treatment intervals ranging from 4 to 40 weeks.
- Clinical photographs were graded by 3 outside board-certified dermatologists using a 5-point visual analog scale.

RESULTS

- Overall, patients were rated to have a mean improvement of 26%–50%.
- Two patients (FST III and VI) achieved 100% clearance after 4-5 treatment sessions.
- The 730-nm picosecond titanium sapphire laser is both a safe and effective treatment option, in the right morphologic setting, to improve the cosmetic appearance of CALMs in a wide range of ages and all skin types.

 Open Access <https://onlinelibrary.wiley.com/doi/10.1002/lsm.23769>

Alajmi A, Niaz G, Lee K, Bernstein EF. JAAD Case Rep. 2023 Nov 30;43:62-68.

*PicoWay 730 nm & 785 nm HPs
Benign Pigmented Lesions*

CASE SERIES DETAILS

- Three subjects (age range 66-72 years, FST I-II) with minocycline-induced skin pigmentation on the face were treated with both nanosecond-domain and picosecond domain lasers using a variety of wavelengths.

RESULTS

- Inconsequential response to the Q-switched laser seen in 2 of the 3 patients.
- Case 1: 1064 nm Nd:YAG Q-switched laser treatment had no improvement, additional 3 treatments with 730 nm Ti:sapphire laser achieved pigment clearance.
- Case 2: After Nd:YAG Q-switched laser treatment achieved minimal improvement, treatment with 785 nm Ti:sapphire laser treatment showed significant improvement and additional treatment with 730 nm Ti:sapphire laser achieved dramatic clearing of the pigment.
- The 730 nm wavelength which emits the shortest picosecond-domain pulse currently available in the market, highlights the potential benefits of ultrashort pulse durations in achieving superior outcomes with minimal photothermal effects.



Effectiveness of 730 nm Picosecond Laser for the Treatment of Freckles and Solar Lentigines: A Retrospective Analysis

Che Q, Wa Q, Liu L, et al. *Dermatologic Therapy* 2023.1 (2023): 2070560.

*PicoWay 730 nm HP
Lentigines & Benign Pigmented Lesions*

STUDY DETAILS

- Fifty patients (45 females, 5 males; mean age of 32.0 years; FST III-IV) with freckles and solar lentigines were retrospectively evaluated after two treatments with 730 nm picosecond laser (PicoWay, Candela). The treatment parameters were set at 1.5–1.8 J/cm², 1 Hz, and 250 ps.
- Clinical evaluation included: lesion clearance and recurrence rates, adverse reactions, and patient satisfaction.

RESULTS

- The lesion clearance rates after one and two treatments were 53.1% and 78.4%, respectively, and the rates after one and six months of treatment were 78.7% and 78.4%, respectively.
- 90% of the patients reported ≥95% clearance of lesions after six months via a questionnaire survey.
- Post-inflammatory hyperpigmentation appeared in two patients, both of whom had Fitzpatrick skin type IV. Topical application of hydroquinone accelerated remission.
- There was no recurrence of lesions.
- Among the patients, 86.0% were satisfied with their treatment.

 Open Access <https://onlinelibrary.wiley.com/doi/full/10.1155/2023/2070560>

Comparison of the efficacy and safety of a 730 nm picosecond titanium sapphire laser and a 755 nm picosecond alexandrite laser for the treatment of freckles in Asian patients: A two-center randomized, split-face, controlled trial

Zhang M, Zheng H, Ge Y, et al. Lasers Surg Med. 2023 Sep;55(7):636-641.

*PicoWay 730 nm HP
Benign Pigmented Lesions*

STUDY DETAILS

- 86 Asian subjects (mean age 30.70 years; 7 males, 79 females; FST III-IV) with freckles were enrolled to a prospective, split-face comparison study.
- Each side of the subject face was randomly assigned for one treatment with either 730 nm (PicoWay, Candela) picosecond (PS) laser (Fluence 1.80–4.00 J/cm²; spot size 2.0–3.0 mm) or 755 nm (PicoSure, Cynosure) PS laser (Fluence 3.77–4.80-J/cm²; spot size 2.3–2.6 mm).
- Efficacy and safety were determined based on blinded visual evaluations and self-reports at each follow-up visit (1, 4, and 8 weeks after treatment).

RESULTS

- Both 730 nm and 755 nm PS lasers showed comparable lesion clearance (68.99 ± 7.42% and 69.27 ± 7.75% average clearance, respectively) and with similar Global Aesthetic Improvement Scale scores (moderate improvement; 4.04 ± 0.31 vs. 4.02 ± 0.30, respectively; p > 0.05).
- >60% lesion clearance was found in 95.3% and 91.9% of the 730 and 755 nm PS lasers, respectively (p = 0.97).
- The 730 nm laser was less painful than the 755 nm laser with average VAS of 4.69 ± 1.63 vs. 5.65 ± 1.80, respectively (p < 0.0001).



Melasma treatment with a 1064 nm, picosecond-domain laser with a fractionated multibeam lens array

Bernstein EF, Basilavecchio LD, Wang J. Lasers Surg Med. 2023 Sep 5.

*Resolve 1064 nm HP
Melasma*

STUDY DETAILS

- 20 adults (18 female; mean age of 42 ± 6.7 years; FST III–VI) with a clinical diagnosis of melasma received 4 monthly treatments using PicoWay with the Resolve 1064 nm handpiece (Fluences 1.7–2.9 mJ/microbeam; repetition rate of 6–8 Hz; 353–1453 pulse per treatment)
- Efficacy was evaluated by 3 dermatologists blinded to the treatment conditions comparing baseline and 3- and 8-month post-treatment digital images
- Modified melasma area and severity index (mMASI) scores were determined by the study investigator based on clinical photography. Subject self-assessment of treatment effects was also recorded

RESULTS

- Blinded reviewers correctly identified the post-treatment image in 16 of the 20 image sets (80%)
- Significant ($p < 0.001$) improvement on an 11-point scale at both the 3- and 8-month timepoints, with a mean improvement of 3.7 point (range –8 to 10) or 37% improvement at the 3-month follow-up, and 2.7 (range –8 to 9) or 27% at the 8-month follow-up
- The average mMASI score showed highly significant reduction at both the 3- and 8-month follow-up visits compared to baseline ($p < 0.01$)
- Most subjects (90%) were satisfied with the outcome at follow-up visits

 Open Access <https://onlinelibrary.wiley.com/doi/10.1002/lsm.23723>

Characterization of picosecond laser-induced optical breakdown using harmonic generation microscopy

Liu C, Wu PJ, Chia SH, Sun CK, Liao YH. Lasers Surg Med. 2023 Aug;55(6):561-567.

Resolve 1064 nm HP
Histological & HGM Examination

STUDY DETAILS

- Histopathological changes of the skin of 5 subjects (FST III-IV) were examined after treatment with PicoWay laser (Resolve 1064 nm handpiece) using the following methods:
 - *ex Vivo* histological analysis: freshly excised, full-thickness skin specimens from the buttocks / thighs were treated with laser irradiation and immediately fixed in 10% formaldehyde solution
 - *in Vivo* histological examination: The laser-treated skin on the left thigh of a male participant was excised, fixed, and sent for pathological examination
 - *in Vivo* harmonic generation microscopy imaging (HGM): A laser shot was administered on the volar forearms and the skin areas were observed under HGM 1 hour later

RESULTS

- Histological H&E staining and HGM imaging revealed the presence of epidermal vacuoles below the stratum granulosum along with keratinocyte degeneration or cytolysis
- HGM imaging showed laser-induced shock wave propagation immediately beneath the epidermal vacuoles
- PicoWay Resolve 1064 nm laser generated epidermal vacuoles and induced collagen changes. These collagen changes may lead to dermal remodeling and neocollagenesis underlying the picosecond laser treatment
- The epidermal and dermal microinjuries can improve skin texture, wrinkles, acne scars, and dyspigmentation without disrupting the epidermal surface



Retrospective Review of the Laser Removal of Facial Cosmetic Tattoos

Hartman N, Loyal J, Borsack S, Goldman MP, Boen M. Dermatol Surg. 2023 Jun 1;49(6):559-565.


1064 nm & 532 nm HPs
Cosmetic Tattoos

STUDY DETAILS

- A retrospective review chart of the safety and efficacy of picosecond (PS) laser for removal of difficult to treat cosmetic facial tattoos
- 33 patients (32 females; FST I-IV) that were undergoing cosmetic tattoo removal on their face using PicoWay laser were evaluated. 21, 11, and 1 of the patients underwent tattoo removal for eyebrow, eyeliner, and lip liner tattoos, respectively. All subjects underwent at least 1 laser treatment and returned in follow-up after last treatment
- Brown and black tattoos were treated using 1064 nm wavelength (Fluence 1.2-12.5 J/cm²; spot size 2-4 mm)
- Orange, red, pink, and yellow tattoos, resulting from unmasking colors, were treated using the 532 nm wavelength (Fluence 0.6-3 J/cm²; spot size 2-4 mm)
- In a few cases, a fractionated CO₂ laser was used after the PS laser

RESULTS

- PicoWay was efficacious in clearing cosmetic tattoos. The under-reported unmasking of an orange color post laser treatment can be successfully treated with a 532-nm PS laser
- The average number of treatments to obtain satisfactory results was 3
- 66% percent of subjects were rated as “very much improved” with 76% to 100% of the tattoo removed and 34% of subjects were rated “much improved” with 51% to 75% of the tattoo removed
- 30% of subjects experienced unexpected changes in the tattoo color after initial treatment with 1064-nm PS laser



Characterization of picosecond laser-induced optical breakdown using harmonic generation microscopy

Liu C, Wu PJ, Chia SH, Sun CK, Liao YH. Lasers Surg Med. 2023 Aug;55(6):561-567.

*Resolve 1064 nm HP
Harmonic Generation Microscopy*

STUDY DETAILS

- Five participants having skin phototype III-IV were recruited for intervention using a picosecond 1064-nm Nd:YAG laser system (PicoWay Resolve 1064 nm handpiece).
- The laser-induced histopathological changes on human skin were examined in vivo using a harmonic generation microscopy (HGM), visualizing second harmonic generation (SHG), and third harmonic generation (THG) contrasts dichromatically.
- SHG refers for collagen distribution, while THG represents for epidermal components in the HGM signal.

RESULTS

- Histological hematoxylin and eosin staining, and in vivo HGM imaging studies revealed the presence of epidermal vacuoles below the stratum granulosum along with keratinocyte degeneration or cytolysis.
- HGM imaging exclusively demonstrated laser-induced shock wave propagation arranged as a THG-bright concentric pattern in the epidermis and loss of SHG signals in the papillary dermis immediately beneath the epidermal vacuoles.
- Alongside generating epidermal vacuoles, **the picosecond 1064-nm Nd:YAG laser induced collagen changes. These collagen changes may lead to dermal remodeling and neocollagenesis underlying the picosecond laser treatment.**



Comparison of Picosecond and Nanosecond Nd:YAG 1064-nm Lasers in the Treatment of Melasma: A Split-Face Randomized Clinical Trial

Feng J, Huang L. *Plast Reconstr Surg.* 2023 Apr 1;151(4):772-777.

*Resolve 1064 nm HP
Melasma*

STUDY DETAILS

- 18 patients (mean age 41 ± 5 years; FST III-IV) diagnosed with melasma (9 ± 5 years) were enrolled to a prospective, split-face comparison study
- Each side of the face received 4 monthly treatments with nanosecond Q-switched Nd:YAG (QSNY) 1064 nm laser (MedLite C6) or picosecond Nd:YAG (PSNY) 1064 nm laser (PicoWay)
- The modified Melasma Area Severity Index (mMASI) was assessed at baseline and the 3-month follow-up visit
- The recurrence rate and the patients' self-satisfaction assessment were also evaluated

RESULTS

- Both treated sides showed significant decreases in mMASI score after treatment compared with baseline ($P < 0.001$)
- Pain assessment score showed that the QSNY was more painful than PicoWay-treated side ($P = 0.007$)
- Five patients (31.3%) experienced acneiform eruption on the QSNY-treated side
- The recurrence rate was the same for the two treated sides (12.5%) but 2 enrollees dropped out of the study because of worsening melasma on the QSNY treated side
- The authors concluded that **PicoWay was found to be a better choice compared with QSNY with less treatment pain and post-procedure erythema as well as lower potential risk of exacerbation of melasma**

Comparison of the Efficacy and Safety of Picosecond Nd:YAG Laser (1,064nm), Picosecond Alexandrite Laser (755nm) and 2% Hydroquinone Cream in the Treatment of Melasma: A Randomized, Controlled, Assessor-Blinded Trial

Liang S, Shang S, Zhang W, et al. Front Med (Lausanne). 2023 Mar 28;10:1132823

Zoom 1064 nm HP
Melasma

STUDY DETAILS

- 60 female patients with melasma, aged between 18-65, with FST III-IV were randomly assigned to be treated with the PicoWay laser with the Zoom 1064 nm Handpiece, non-fractional picosecond 755 nm alexandrite laser (PicoSure; Cynosure), or 2% HQ cream (QianBai; REEKON, Guangdong, China) at a 1:1:1 ratio
- Laser treatment included 3 laser sessions at 4-week intervals. The 2% HQ cream was applied twice daily for 12 weeks by patients in the HQ group
- The melasma area and severity index (MASI) score was evaluated at weeks 0, 4, 8, 12, 16, 20, and 24, by two trained independent physicians, blinded to the group allocation of the patients
- The patient assessment score by quartile rating scale (0 = no improvement or worsening to 4 = 75 to 100% improvement) was assessed in weeks 12, 16, 20, and 24

RESULTS

- **At week 24, the MASI score in the PicoWay laser group showed the greatest improvement** (least squares mean difference [95% CI]) compared to the non-fractional picosecond 755 nm alexandrite laser group (-1.3 [CI, -2.4 to -0.2]; p=0.016) and HQ group (-1.3 [CI, -2.4 to -0.2]; p=0.018)
- The mean change (SE) in MASI score from baseline was the most for the PicoWay laser group, with -5.6 (0.6), 35.9%, p<0.001 at week 24
- The **PicoWay laser group showed the highest patient assessment improvement score**
- Laser treatments were well tolerated, with no significant difference in pain scores between laser groups

 Open Access <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086227/>

Picosecond neodymium-doped yttrium-aluminum-garnet laser therapy for pigmentation due to lichen planus pigmentosus in a patient with skin of color

Belzer A, Swallow MA, Gowen M, Suozzi KC. JAAD Case Rep. 2023 Feb 13;34:45-47.

*PicoWay Zoom 1064 nm & 785 nm HPs
Pigmented Lesions*

CASE STUDY DETAILS

- A 73-year-old female with skin of color and diagnosed with lichen planus pigmentosus (LPP), demonstrated deeply pigmented skin with hundreds of 1 to 3 mm dark brown to gray-brown macules coalescing into large patches without scale on the face
- Prior to laser treatment: 2.5% hydrocortisone was applied twice daily for 1 month and simvastatin was discontinued
- Treatment included: 10 laser treatments with PicoWay Zoom 1064 nm, ~1-month apart (Fluence 2.0-2.4 mJ; spot size 3-4 mm; 459-1212 pulses per treatment) & 4 treatments with 785 nm (Fluence 0.6-1.5 mJ; spot size 3-4 mm; 530-755 pulses per treatment)
- Post treatment care included: Ice packs after treatment in office and hourly for the rest of the day. Hydrocortisone 2.5% cream was applied twice daily for 3-5 days after treatment

RESULTS

- Significant improvement of pigmentation reported on both patient and provider evaluation
- Most notable decrease in pigmentation across the nose and blending of previously sharp demarcation between the pigmented macules and normal skin
- Mild swelling was seen following treatments
- No dyspigmentation or scarring developed

 Open Access <https://pubmed.ncbi.nlm.nih.gov/36936863/>

Evaluation of the safety and efficacy of a fractional picosecond 1064 nm laser for post-acne erythema in adult Chinese patients

Jia X, Zheng L, Fang L, et al. Skin Res Technol. 2023 Jan;29(1):e13274.

*Resolve 1064 nm HP
Acne Scars, Erythema*

STUDY DETAILS

- 22 Chinese patients (20 females; 2 males) with mean age 30.55 ± 4.58 and FST III-IV, diagnosed with post-acne erythema (PAE), received a single PicoWay treatment using the Resolve 1064 nm handpiece and were followed up at the 8th week
- Clinician erythema assessment scale (CEAS; 0=Clear to 4=Severe), global aesthetic improvement scale (GAIS; 0=Worsened patient to 4=Exceptional improvement) and patients' assessment of satisfaction on a five-point scale (0 Not satisfied to 4 Extremely satisfied) were evaluated
- VISIA automatic analysis of digital photography was also used to evaluate erythema percentile ratings at baseline and follow-up

RESULTS

- The mean CEAS scores fell from 2.74 ± 0.80 to 1.95 ± 0.75 ($p < 0.001$)
- The mean GAIS of PAE improvement was 2.46 ± 0.68
- Erythema percentile scores by VISIA increased from 32.63 ± 7.0 to 45.75 ± 11.45
- The patient satisfaction score was 1.86 ± 1.17 and the average pain scores was 3.27 ± 1.17 (range 2 to 6)
- Moderate erythema and oedema, lasted for 3.84 ± 0.78 days after treatment, 68.18% (15/22) of patients felt pruritus in different degrees and 27.27% of patients encountered acne eruptions (white head type)
- No scar, hyperpigmentation or hypopigmentation was found

 Open Access <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155796/>

Randomized, evaluator-blinded comparative study of a potassium titanyl phosphate (KTP) 532-nm picosecond laser and an alexandrite 755-nm picosecond laser for the treatment of solar lentigines in Asians

Vachiramon V, Namasondhi A, Anuntrangsee T, Jurairattanaporn N. J Cosmet Dermatol. 2022 Oct;21(10):4370-4377.

*PicoWay 532 nm HP
Lentigines*

STUDY DETAILS

- 30 subjects (5 males, 25 females, mean age 63 years, Fitzpatrick Skin Types III-IV) with at least 2 solar lentigines \geq 5-mm in diameter on the upper extremities were enrolled
- Paired lentigines were treated with PicoWay Zoom 532 nm handpiece (3 mm spot size, energy fluence of 0.3–0.9 J/cm² at 1 Hz) and alexandrite 755-nm picosecond laser (3 mm spot size, energy fluence of 2.83 J/cm²)
- Objective assessment was performed with a colorimeter to measure the luminance score (L*)
- 1 blinded dermatologist assessed degree of pigment clearance on a scale of 0 to 4: 0 = no improvement; 4 = excellent improvement (75–100%)

RESULTS AT 6 AND 12 WEEKS AFTER TREATMENT SERIES

- Both lasers showed significant improvement in mean L* from baseline ($p < 0.001$)
- At the 12-week follow-up, 13 lesions (43.3%) treated with the PicoWay laser were rated as over 75% pigment clearance
- All lesions showed crust formation that peeled off within 1-2 weeks
- Post-inflammatory hyperpigmentation developed in one patient treated with alexandrite 755 nm laser (3.3%) and two patients (6.7%) treated with PicoWay at the 3-month follow-up

The effect of a dual-wavelength 532 nm and 1064 nm picosecond-domain laser with a fractionated holographic optic on photoaging and patient age perception: A pilot study

Leight-Dunn H, Hadi A, Patel F, et al. J Cosmet Dermatol. 2022 Jan;21(1):320-326.

*Zoom 532 nm
Resolve 532 nm & 1064 nm HPs
Photoaging*




STUDY DETAILS

- 13 subjects (1 male, 12 female; mean age 55.84 ± 5.84 ; Fitzpatrick skin type II-IV) with moderate-to-severe facial dyspigmentation and wrinkles were enrolled and treated
- 3-monthly treatments: spot treatment of lentigines with the Zoom 532 nm HP (3 mm spot, fluence ranged from 0.4-1.2 J/cm²), followed by 2 passes (horizontal and vertical) with the Resolve 1064 nm HP (1.9-2.3 mJ/μbeam) and 2 passes with the Resolve 532 nm HP (0.4–0.8 mJ/μbeam)
- Blinded reviewer and investigator evaluation of pre-and post-treatment images sets at 12 weeks after the final treatment

RESULTS AT 12 WEEKS AFTER TREATMENT SERIES

- Blinded physicians correctly identified baseline images in 44 of 50 (88%) image sets (10 subjects; five reviewers)
- Investigator assessments showed significant improvement of pigmentation ($p=0.0042$) and rhytids ($p=0.0196$)
- Mean investigator improvement in overall facial photoaging score was 3.3
- 80% of participants reported satisfaction with the treatment
- Adverse events were mild; one patient developed hyperpigmentation, consistent with melasma that was successfully treated with topical agents

 Open Access <https://pubmed.ncbi.nlm.nih.gov/34908229/>



Comparison of 1064-nm and Dual-Wavelength (532/1064-nm) Picosecond-Domain Nd:YAG Lasers in the Treatment of Facial Photoaging: A Randomized Controlled Split-Face Study

Zhang M, Huang Y, Wu Q, Lin T, Gong X, Chen H, Wang Y. Lasers Surg Med. 2021 Nov;53(9):1158-1165.

*Resolve Treatment &
Histological Evaluation
Wrinkles*

STUDY DETAILS

- 21 Chinese females (mean age 53±7 years) with Fitzpatrick skin type III (n=7) and IV (n=13) and moderate to severe facial photoaging underwent PicoWay Resolve treatments and completed the follow-up visits
- 5 monthly treatments to a random half of the face with the Resolve 1064nm handpiece (2 passes, 2.1 mJ/μbeam and 2 Hz), while the contralateral half of the face was treated with 2 passes with the Resolve 532nm handpiece (0.2 mJ/μbeam and 2 Hz) followed by 2 passes with the Resolve 1064nm handpiece (2.1 mJ/μbeam and 2 Hz)
- 2 blinded physicians evaluated the digital clinical images, based on the 5-point global score for photoaging, at 1 and 3 months after the final treatment
- Subjects assessed improvement, using a 5-point Global Aesthetic Improvement Scale (GAIS) of 0 = worsening to 4 = significant improvement
- 4 women had cheek skin biopsies of the treated areas before and within 24 hours of treatment or at 1 month after

RESULTS AT 1- and 3-MONTH FOLLOW-UP AFTER TREATMENT SERIES

- Compared with baseline, the global photoaging scores decreased significantly with either laser treatment, at the 1-month and 3-month follow-up visits (P < 0.001)
- The global photoaging scores, GAIS scores, and satisfaction scores did not differ significantly between the Resolve 1064 nm and combined Resolve 532/1064 nm treatments
- Neocollagenesis was observed in the upper dermis of both treatment groups, and elastic fibers were more elongated and orderly



Treatment of nevus of Ota with 1064 nm picosecond Nd:YAG laser: A retrospective study

Yang H, Guo L, Jia G, Gong X, Wu Q, Zeng R, Zhang M, Ding H, Fang F, Zheng H, Liu X, Ge Y, Yang Y, Lin T. *Dermatol Ther.* 2021 Nov;34(6):e15152.

*PicoWay 1064 nm HP
Nevus of Ota*

RETROSPECTIVE STUDY DETAILS

- 16 Chinese patients [8 male; 8 female; mean age 16.87 years (4 months to 59 years); Fitzpatrick skin type IV] with nevus of Ota (11 brownish lesions; 5 blue-black lesions) were treated with the 1064 nm handpiece
- Total treatment ranged from 1 to 5 sessions at 3–12 months intervals (mean fluence of 1.8–4.3 J/cm², 3–4 mm spot size, 5 Hz)
- Blinded evaluation of clinical photography by 3 independent dermatologists, using a 5-point pigment clearance scale: 1 = poor (0%–24%) to 5 = complete (95%–100%)

RESULTS

- The mean efficacy score was 2.56 after one session (n=16), 3.15 (n=13) after two sessions and 3.51 (good to excellent clearance) after 3 sessions (n=9)
- The clearance of blue-black lesions was significantly better than that of brownish lesions (p = 0.001)
- All patients were “very satisfied” (62.5%, 10/16) or “satisfied” (37.5%, 6/16) with treatment
- Postinflammatory hyperpigmentation after treatment was observed in 1 patient (1/16, 6.25%) and gradually disappeared. Hypopigmentation was not observed.




Treatment of imipramine-induced hyperpigmentation with quality-switched ruby and picosecond lasers

Hamid RN, Yang RG, Munavalli GS. JAAD Case Reports, 2021 Nov;17:12-17.

*PicoWay 532 nm HP
Benign Pigmented Lesions*

CASE STUDY DETAILS

- A 72-year-old woman presented to the clinic for evaluation of progressive brown and slate-gray hyperpigmentation that had spread over the face and neck after taking imipramine for >20 years
- The patient underwent a series of 3 treatments, over a period of 17 months, with the PicoWay 532 nm picosecond laser (1.2 – 1.5 J/cm² and 4 mm spot size) to the forehead, cheeks, and temples
- Moderate improvement in brown hyperpigmentation following the treatments series
- After a 2-month imipramine taper, the patient underwent 3 treatments with a Q-switched ruby laser (694 nm, 5 mm, 3-4 J/cm²) and exhibited a significant reduction in slate-gray hyperpigmentation on the cheeks
- After 1 final treatment with the PicoWay 532 nm picosecond laser (1.8 J/cm² and 3 mm spot size), there was nearly complete resolution of hyperpigmentation to the forehead, cheeks, and temples
- Purpura developed after 1 PicoWay treatment with high fluence that resolved after a single session of pulsed dye laser (Vbeam® Perfecta, Candela Corporation)
- The patient experienced resolution of pigmentation over a 3-year treatment period without recurrence despite the resumption of low-dose imipramine therapy



Fractional 1064 nm Picosecond Laser in Treatment of Melasma and Skin Rejuvenation in Asians, A Prospective Study

Wong CSM, Chan MWM, Shek SYN, Yeung CK, Chan HHL. Lasers Surg Med. 2021 Oct;53(8):1032-1042.


*Resolve 1064 nm Treatment
Melasma & Wrinkles*

STUDY DETAILS

- 20 Chinese females with Fitzpatrick skin type III (n=3) and IV (n=17) and average age of 52.7 years were treated for melasma (n=10) and signs of photoaging (n=10)
- 9 treatments with the PicoWay Resolve 1064 nm laser (4 passes, 1.3 – 1.9 mJ/μbeam, 5-10 Hz)
- 2 blinded investigators calculated scores for the Modified Melasma Area and Severity Index (mMASI) and an Investigator Global Aesthetic Improvement Scale (IGAIS) for overall reduction in fine lines, rhytids, wrinkles, dyspigmentation, and pore size

RESULTS AT 6 AND 12 WEEKS AFTER TREATMENT SERIES

- Statistically significant improvement in mMASI (10.8 at baseline to 2.7 and 3.6), at 6- and 12-weeks posttreatment, respectively (both $P < 0.01$)
- 90% of subjects treated for wrinkles and dyspigmentation (photoaging) showed some degree of improvement on IGAIS at follow-ups, while 40% showed at least moderate improvement at the 12-week follow-up
- No hypo- or hyperpigmentation after treatment



Histological Characteristics of Skin Treated With a Fractionated 1064-nm Nd: YAG Picosecond Laser With Holographic Optics

Zhang M, Guan Y, Huang Y, Zhang E, Lin T, Wu Q. Lasers Surg Med. 2021 Oct;53(8):1073-1079.

*Resolve 1064 nm HP
Histological Evaluation*

STUDY DETAILS

- *In vivo* back skin specimens of 3 volunteers, aged 60, 62, and 65 years, were treated, using the Resolve 1064 nm HP at low (1.3 mJ/μbeam), medium (2.1 mJ/μbeam), and high (2.9 mJ/μbeam) fluence for 2 passes and at 2.9 mJ/μbeam with 10 passes
- Fresh *ex vivo* human foreskin specimens were obtained following circumcisions in Chinese men with Fitzpatrick Skin Types III-IV and treated with the Resolve 1064 nm HP at low (1.3 mJ/μbeam), medium (2.1 mJ/μbeam), and high (2.9 mJ/μbeam) fluence for 2 passes and at 2.9 mJ/μbeam with 10 passes

RESULTS AT 24 HOURS POST TREATMENT

- *In vivo*: Intraepidermal vacuoles (20 to 200 μm in diameter) were observed, along with pigment accumulation and inflammatory cell infiltration in the vacuoles. The vacuoles expanded as the fluence increased.
- Numerous intraepidermal vacuoles were observed, with dermal hemorrhage and inflammatory cell infiltration upon high fluence, multi-pass treatment. Vascular damage and red blood cell extravasation were consistent with the skin erythema and petechiae observed clinically
- The surrounding tissue around the vacuoles retained its structural integrity during this process
- *Ex vivo*: Both epidermal and dermal vacuoles (20 to 250 μm in diameter) were observed, with Melan-A-positive cells in the cystic wall of vacuoles in the epidermal basal layer, and CD31-positive cells in the cystic wall of some dermal vacuoles



Safety and Efficacy of Tattoo Removal Using a Dual-Wavelength 1064/532-nm Picosecond Laser in Patients With Fitzpatrick Skin Type III and IV

Nguyen HT, Doan EVL, Tran TNA, Vu TTP, Phan HN, Sobanko JF. Lasers Surg Med. 2021 Sep;53(7):939-945.

*PicoWay 1064 and 532 nm HPs
Tattoos*

STUDY DETAILS

- 30 males and females (mean age 28 years), with 52 decorative tattoos primarily on the shoulders, back, arms, and thighs, were enrolled
- Up to 6 treatments, at 6 to 8-week intervals, with the PicoWay 1064 nm HP (black, blue, and green dyes) and PicoWay 532 nm HP (red and yellow tattoos), using spot sizes of 3–6 mm, 1–5 Hz and average fluence of 2.7 – 2.9 J/cm² (1064 nm HP) and 1.05 – 1.12 J/cm² (532 nm HP)
- Blinded evaluation by 3 physicians of photographic improvement of pre- and 1-month post final treatment, categorized as complete response (100% clearance), very good response (>90% clearance), good response (≥75% clearance), or partial response (<75% clearance)

RESULTS AT 1-MONTH FOLLOW-UP AFTER FINAL TREATMENT

- Blinded assessment showed a significant reduction of tattoo appearance for all subjects
- 88.5% (n=46) of tattoos exhibited a “good” response to treatment, with >36% (n=23) of tattoos exhibiting a very good or complete response
- Short-term adverse events were common but resolved without intervention. Higher energy PicoWay 532 nm treatment had increased incidence of immediate side effects (bulla formation, petechiae, edema)
- No hyperpigmentation, scarring, or keloids. 1 case of prolonged hypopigmentation after 3 months of treatment



Treatment of facial and non-facial lentigines with a 730 nm picosecond titanium: sapphire laser is safe and effective

Kauvar ANB, Sun R, Bhawan J, Singh G, Ugonabo N, Feng H, Schomacker K. Lasers Surg Med. 2021 Aug 17.

*PicoWay 730 nm HP
Lentigines*

STUDY DETAILS

- 16 subjects (4 males, 12 females, mean age 63 years, Fitzpatrick Skin Types II-III) underwent 4 monthly treatments to 30 body sites with 118 treated areas and were evaluated at a 12-week follow-up
- The 1st PicoWay treatment with the 730 nm handpiece was administered with an average beam diameter of 2.9 mm and fluence of 2.2 J/cm². Laser fluences were successively increased to 3.9 J/cm² and spot size reduced to 2.0 mm for the 4th treatment
- Blinded evaluation by 3 physicians of photographic improvement of pre- and 1- and 3-month post-treatment digital images, using a 5-point scale (0 = 0% clearance, 4=75%–100% clearance (excellent response))
- Investigator Global Improvement Score (IGIS), using an 11-point clearance scale (0 = no improvement, up to a score of 10 = 100% improvement (complete clearance))
- 9 biopsies taken after treatment with 730 and 532 nm picosecond pulses and 755 and 532 nm nanosecond pulses

RESULTS AT 12 WEEKS AFTER TREATMENT SERIES

- 100% of posttreatment images were correctly identified from their respective baseline images
- On average, 73% of treatment areas achieved ≥50% clearance at the 12-week post treatment follow-up
- Mean IGIS score of 7.0
- Mild to moderate erythema and edema were common after treatment
- Histology showed better confinement of thermal energy with picosecond lasers compared to nanosecond lasers

The efficacy and safety of fractional 1064 nm Nd:YAG picosecond laser combined with intense pulsed light in the treatment of atrophic acne scar: a split-face study

Feng H, Wu Y, Jiang M, Luo X, Yan S, Lu Z. Lasers Surg Med. 2021 Jun 3.


*Resolve 1064 nm Treatment
Acne Scars*

STUDY DETAILS

- 15 patients (10 females, 5 males; mean age 22.5 years; Fitzpatrick Skin Types III and IV), with atrophic acne scars accompanied by post-inflammatory erythema (PIE), underwent 5 monthly treatments and were evaluated at 3 months after treatment
- Both sides of the face were treated first with an IPL device (M22™, Lumenis®) followed by treatment to a random side of the face with the Resolve 1064 nm handpiece (3-4 passes with 6 Hz, 1.5-2.5 mJ/μbeam)
- 2 blinded dermatologists calculated the ECCA Scale (échelle D'évaluation Clinique des Cicatrices D'acné) by assessing standard photography
- Pore counts and erythema scores at baseline and follow-up were collected by VISIA® software's automatic analysis


RESULTS AT 3 MONTHS AFTER TREATMENT

- Combined Resolve + IPL-treated side showed significant ECCA score improvement ($P < 0.01$), while IPL alone side did not ($P = 0.1250$)
- Significantly more pore count reduction and scar improvement were seen on the combined treatment side compared to IPL only treated side ($P < 0.05$)
- Statistically significant improvement in erythema ($P < 0.05$) on both sides of the face
- No blistering, pigmentation alternation, scarring, or infection were observed for either side



<https://pubmed.ncbi.nlm.nih.gov/34082477/>

PicoWay® Resolve



Comparison of fractionated frequency-doubled 1,064/532 nm picosecond Nd:YAG lasers and non-ablative fractional 1,540 nm Er: glass in the treatment of facial atrophic scars: a randomized, split-face, double-blind trial

Shi Y, Jiang W, Li W, Zhang W, Zou Y. Ann Transl Med. 2021 May;9(10):862.

*Resolve Treatment
Acne Scars*

STUDY DETAILS

- 22 Fitzpatrick skin type IV patients (4 males, 18 females) were included in this study, with an average age of 29.7 years and an average duration of acne scars of 8.8 years
- 4 monthly treatments to a random half of the face with the PicoWay Resolve 1064 nm (1.7 – 1.9 mJ/μbeam) or Resolve 532 nm (0.2 – 0.22 mJ/μbeam) laser with 10 Hz repetition rate and to the contralateral side with a non-ablative fractional 1540 nm Er: glass laser (StarLux™, Palomar) and energy of 65 – 70 J/cm², each spot overlapped 10%, and treatment area scanned 4 times (NAFL treatment)
- 2 blinded physicians calculated the ECCA Scale (échelle D'évaluation Clinique des Cicatrices D'acné) by assessing standard photography
- Skin flatness (acne scar height) was measured with a 3-D imaging system (PRIMOS)

RESULTS AT 1 MONTH AFTER TREATMENT SERIES

- PicoWay treatment significantly impacted all acne scar types (P=0.0001), with a more pronounced effect on ECCA score than non-ablative laser for V-type and U-type acne scars
- PicoWay treatment significantly reduced acne scar height (P=0.041), while NAFL did not (P=0.785)
- Greater patient satisfaction with pore size appearance and atrophic scars after PicoWay treatment compared to NAFL

Novel application of the 730 and 785 nm picosecond titanium sapphire lasers for the treatment of Nevus of Ota

Loh TY, Wu DC. Lasers Surg Med. 2021 Mar 25.

*730 nm & 785 nm HPs
Benign Pigmented Lesions*

CASE STUDY 1

- A 22-year-old Asian female with Fitzpatrick skin type III presented for laser removal of a nevus of Ota on the left cheek
- The patient underwent 4 monthly sessions with the PicoWay 730 nm HP (4 passes with 1.8 J/cm² and 3 mm spot size for the 1st treatment and 4 passes with 1 J/cm² and 4 mm spot size for successive treatments)
- At 1 month follow-up after 4th PicoWay 730 nm treatment, there was 75% resolution of the nevus of Ota
- No post-inflammatory pigmentary changes or adverse side effects throughout treatment

CASE STUDY 2

- A 43-year-old Asian female with Fitzpatrick skin type IV presented for laser removal of a nevus of Ota on the left cheek
- No significant improvement after 2 initial monthly sessions with 755 nm picosecond Alexandrite laser (Picosure®, Cynosure) with 2.33 J/cm² and 3 mm spot size
- No significant improvement after 2 monthly sessions with PicoWay 1064 nm spot treatment of focal hyperpigmentation (4.30 J/cm² and 3 mm spot size) and PicoWay 1064 nm treatment of diffuse hyperpigmentation with 4 passes of 0.60 J/cm² and 6mm spot size
- After 3 months of no treatment, the patient underwent 3 sessions with the PicoWay 785 nm HP (4 passes with 1 J/cm² and 3 mm spot size)
- At 2 months follow-up after PicoWay 785 nm treatments, there was near-complete resolution of the nevus of Ota
- No post-inflammatory pigmentary changes or adverse side effects throughout treatment

Dual toning method with the combination of picosecond and microsecond Nd:YAG in refractory melasma unresponsive to picosecond alone

Hai L, Phuong B, Ha L, Lam V, Van B, Al-Niaimi F. J Cutan Aesthet Surg. 2021 Jan-Mar;14(1):101-106.

*PicoWay 1064 nm HP
Benign Pigmented Lesions*

STUDY DESIGN

- 20 Vietnamese females with Fitzpatrick skin type IV, age ranging from 31 to 58 years (mean 41.9 ± 6.4 years), presented with severe dermal and mixed-type melasma that was unresponsive to 8 sessions of picosecond laser treatment alone
- Patients underwent 3 monthly combined treatments with PicoWay 1064 nm HP (2-3 passes with $0.6 - 0.8$ J/cm², 8 mm spot size, 10 Hz repetition rate, and 20–30% overlap) followed immediately by multiple stacked passes with a microsecond Nd:YAG laser (Clarity™, Lutronic) with a 15 mm spot size, 0.35 ms pulse duration, 2.6 J/cm², repetition rate of 10 Hz, and cooling off
- 2 blinded independent dermatologists reviewed the clinical photographs to provide Melasma Area and Severity Index (MASI) scores

RESULTS AFTER TREATMENT SERIES

- MASI score reduced by a mean of 5.35 ± 2.64 points and $35.15 \pm 13.51\%$ following the 3 combined treatments
- Patients also noted an improvement in skin tone, smoother skin texture, and uniform pigmentation
- Erythema was mild and transient. No adverse events

Successful Treatment of Scalp Micropigmentation with 1064 nm Picosecond Nd:YAG Laser

Wu DC. Lasers Surg Med. 2020 Dec 1. doi: 10.1002/lsm.23364

1064 nm HP
Ink micro-pigmentation

RETROSPECTIVE CASE SERIES DETAILS

- 4 male patients (age range 42-54 years, skin type II) with 3-15 years experience of undesired scalp micropigmentation (SMP) were treated with the 1064 nm Nd:YAG handpiece for their SMP removal
- Treatment included 1-3 sessions (3-4 weeks apart) with spot size of 4-5 mm and $8,325 \pm 3,376$ pulses
- Post-operative care consisted of 1% dimethicone ointment applied twice daily to the affected areas for 3–7 days

RESULTS AT 3-4 WEEKS AFTER TREATMENT

- Clearance of SMP was achieved with 1 treatment session for 3 subjects and with 3 treatment sessions for 1 subject
- The appearance of scarring and/or baseline photodamage also improved in 2 subjects
- There were no unexpected adverse events



Safety and Efficacy of a Novel 730 nm Picosecond Titanium Sapphire Laser for the Treatment of Benign Pigmented Lesions

Lipp MB, Angra K, Wu DC. Lasers Surg Med. 2020 Sept 1;10.1002/lsm.23314.

730 nm HP
Pigmentation

STUDY DETAILS

- Retrospective review of 22 patients assessed (19 females, 3 males, mean 45±10 years), majority Fitzpatrick Skin Type III (40.9%) and IV (45.5%), out of 64 patients treated for benign pigmented lesions
- Clinical diagnosis of melasma in 68% (15) subjects. Treatment indications included: Solar lentigines = 15 (68%), Seborrheic keratosis = 4 (18%), Dermatitis papulosa nigra = 2 (9%) and ephelides = 1 (5%)
- Mean of 1.1±0.3 treatments with the PicoWay 730 nm titanium-sapphire laser-pumped laser were administered: spot size adjusted to the size of the lesion (mean 2.2±0.4 mm), fluence adjusted to achieve whitening of the target lesions (mean 3.4 ± 1.0 J/cm²)
- Blinded evaluation by 2 physicians of photographic improvement in pigment severity (0: no pigment, 1: light pigment, 2: medium pigment, and 3: dark pigment) and by 2 non-treating investigators for percentage improvement, using a 12-point scale (-1: worse, 10: 100% clearance)

RESULTS AT 4 - 8 WEEKS AFTER TREATMENT

- Statistically significant reduction (p<0.05) in discrete pigmentation (mean 1.39 ± 0.6 versus 2.04 ± 0.7 at baseline)
- 86% of patients showed improvement in pigmentation: 60% had ≥50% improvement
- 1–2 days of mild edema and erythema, 3–5 days of mild pigment darkening and superficial crust
- No hypopigmentation, scarring or prolonged erythema



Localized argyria from silver nasal piercing unresponsive to Q-switched laser successfully treated with a 1064 picoseconds laser

Al-Niaimi F. J Cosmet Dermatol. 2020 Jun;19(6):1535-1536.

1064 nm HP
Silver Pigmentation

CASE REPORT DETAILS

- A 23-year-old woman with a 1-year history of a grayish silvery macule on the right nasal ala, following a silver jewelry nose piercing, underwent a single treatment session
- The macule was asymptomatic and had been unsuccessfully treated with 1064 nm Q-switched laser, prior to her presentation
- Treatment was performed with the 1064 nm wavelength using the nonfractional Zoom handpiece with a 4 mm spot, with 1.8 J/cm² in 2 passes. Erythema was set as an endpoint

RESULTS AT 12 MONTHS AFTER TREATMENT

- The macule gradually disappeared in <2 weeks with no scarring
- No recurrence was seen after 12 months

Histological Characterization of Age-Related Skin Changes Following the Use of Picosecond Laser: Low Versus High Energy

Kirsanova LV, Araviyskaya ER, Rybakova MG, et al. Dermatol Ther 2020 May 21.

*Resolve Treatment
Histological Evaluation*

STUDY DETAILS

- 28 women (mean age 51.3 years, range 36 – 60) with signs of age-related photodamage underwent a picosecond laser treatment with the Resolve 1064 nm handpiece
- Group 1 subjects (n=14) received 4 passes in a horizontal and vertical pattern with low energy fluence of 1.1 mJ/μbeam, while Group 2 (n=14) received high energy treatment (2.1 mJ/μbeam)
- Clinical assessment included skin turgor and texture, wrinkle severity and pore openings
- Histological analysis was performed by 2 independent dermatopathologists

RESULTS AT 3 WEEKS AFTER TREATMENT

- Group 2 showed significant improvement with a more pronounced effect on facial skin than in Group 1
- Histopathological examination demonstrated minimal changes in the epidermis and dermis in Group 1 compared to more pronounced morphological changes in Group 2, with a marked elevation in collagen type III expression antibodies in the high fluence group



A Randomized, Split-Face, Double-Blind Comparison Trial Between Fractionated Frequency-Doubled 1064/532 Nm Picosecond Nd:YAG Laser and Fractionated 1927 Nm Thulium Fiber Laser for Facial Photorejuvenation

Wu DC, Jones IT, Boen M, Al-Haddad M, Goldman MP. Lasers Surg Med. 2020 Apr 14.

Resolve Treatment
Wrinkles

STUDY DETAILS

- 20 subjects (19 females), with mean age 56.5 ± 11.6 [range 40–73] years and Fitzpatrick skin type II–V, were randomly assigned to split-face treatment with PicoWay Resolve (532/1064 nm picosecond lasers) treatment to one side of the face and 1927 nm fractionated thulium fiber laser (TFL) to the contralateral side
- 3 monthly treatments: ½ face 2 passes Resolve 1064 nm laser with energy 1.9 - 2.5 mJ/μbeam, followed by 2 passes with Resolve 532 nm with energy 0.54 - 1.2 mJ/μbeam; ½ face TFL with pulse energy of 20 mJ, treatment levels 3 – 7, correlating with a 30%–50% density, and 8 passes. Forced air-cooling throughout was used for all treatments
- Blinded, non-treating evaluator assessments of photodamage at 6-month follow-up

RESULTS

- Statistically significant improvement was noted in both treatment groups
- Subject 14-day daily diaries showed significantly less downtime (redness, swelling, etc.) associated with Resolve treatments compared to TFL treatments



The first commercial 730 nm picosecond-domain laser is safe and effective for treating multicolor tattoos

Bernstein EF, Schomacker KT, Shang X, Alessa D, Algzlan H, Paranjape A. Lasers Surg Med. 2020 Mar 24.


730 nm HP
Tattoos

STUDY DETAILS

- 15 subjects (5 males, 10 females, mean 45 years, Fitzpatrick Skin Types I-III) with 20 tattoos were enrolled
- 4 treatments with a new 730 nm, titanium-sapphire laser-pumped laser were administered
- Blinded evaluation by 4 physicians of photographic improvement of pre- and 2-month post-treatment cross-polarized digital images, using an 11-point scale in 10% increments (0 = no improvement, 10 = 100% or complete removal)

RESULTS

- Blinded assessment showed 70%, 77%, 83%, 83%, 26%, and 8% clearance from baseline images for black, green, blue, purple, red and yellow pigments, respectively
- Mild edema and erythema immediately after treatment were common
- No scarring or pigmentary alteration visible in any follow-up images



Retrospective Photographic Review of Nontattoo Indications Treated by Picosecond Laser

Mehrabi JN, Friedman O, Al-Niaimi F, Artzi O. J Cosmet Dermatol. 2020 Mar;19(3):612-621.

*PicoWay 532 nm, 1064 nm & Resolve 1064 nm HPs
Melasma, Nevus of Ota, CALMs, Lentigines*

STUDY DETAILS

- Retrospective chart and photographic review of 233 patients (195 females and 38 males) treated with PicoWay and Resolve handpieces for nontattoo indications (i.e. melasma, Nevus of Ota, CALMs, lentigines)
- Number of treatments and parameters were compiled by clinical indication
- Follow-up ranged from 3 to 9 months post final treatment
- 2 blinded, independent physicians evaluated treatment outcome, using a visual analog scale consisting of six levels of treatment response (Grade 0, 0%-5% change to Grade 5, 100% improvement)

RESULTS

- While every type of skin lesion exhibited improvement, there was variability observed in the response to treatment; epidermal nevi exhibited the greatest improvement with treatment, while acne scarring demonstrated the least
- Average number of treatments for all lesions was 3
- Transient pigmentary changes, purpura, blistering were observed. No scarring occurred

Successful treatment of pigmentary disorders in Asians with a novel 730-nm picosecond laser

Lee SJ, Han HS, Hong JK, Park KY, Seo SJ. Lasers Surg Med. 2020 Mar 14.

730 nm HP
Pigmented Lesions

CASE STUDY 1 DETAILS

- Korean female (age 21 years, Fitzpatrick skin type III) with multiple freckles on both cheeks and periorbital area
- Single PicoWay 730 nm picosecond laser treatment with fluence of 1.4 J/cm², 3 mm spot size and single pass with minimum overlap
- At 6 weeks post-treatment, independent evaluation of global assessment, by 2 dermatologists, indicated excellent response (75–94% lightening)

CASE STUDY 2 DETAILS

- Korean female (age 49 years, Fitzpatrick skin type IV) with melasma, freckles, lentigines and erythema on both cheeks and the zygomatic area
- PicoWay 730 nm laser treatment with fluence of 1.7 J/cm² and 3 mm spot size on the disseminated freckles and lentigines and 1064 nm laser treatment, with low fluence of 0.6 J/cm² and 6 mm spot size for the rest of the face
- At 6 weeks post-treatment, independent evaluation of global assessment, by 2 dermatologists, indicated good response (50–74% lightening)

<https://pubmed.ncbi.nlm.nih.gov/32410249/>



A Prospective Study of Fractionated Dual-Wavelength Picosecond Laser in Treating Acne Scars

Yang CS, Huang YL, Cheng CY, Hu S, Chang SL, Lee MC. Lasers Surg Med. 2020 Jan 21.

*Resolve Treatment
Acne Scars*

STUDY DETAILS

- 18 subjects (10 males, 8 females) with acne scarring, skin phototypes III-IV and mean age 30.8 (range 22 - 45) years underwent 6 Resolve treatments
- At each session: full-face treatment with the Resolve 532 nm handpiece at 0.3–0.5 mJ/μbeam fluence and 5Hz frequency, followed by full-face treatment with the Resolve 1064 nm handpiece at 1.5–1.9 mJ/μbeam fluence and 8Hz frequency. The Resolve 1064 nm handpiece was then applied to areas of scarring with high fluence (2.1–2.5 mJ/μbeam)
- 2 dermatologists assessed outcome using the Goodman and Baron's quantitative global acne scarring grading system (GSS)

RESULTS AT 3 MONTHS POST TREATMENTS

- Significant improvement after the 1st treatment ($p < 0.05$) that persisted to the 3-month follow-up
- Subject assessment, using a 5-point Visual Analog Scale, showed improvement from average score of 4.28 at baseline reduced to 2.00 at follow-up
- Transient erythema and swelling, some purpuric spots lasting 2-3 days
- No patient complaints of hyper- or hypo-pigmentation or scarring



<https://pubmed.ncbi.nlm.nih.gov/31960996/>

PicoWay® Resolve



Histology of ex vivo skin after treatment with fractionated picosecond Nd:YAG laser in high and low-energy settings

Yeh YT, Peng JH, Peng P. J Cosmet Laser Ther. 2020 Jan 3:1-5.


*Resolve Treatment
Histological Evaluation*

STUDY DETAILS

- 6 skin samples were taken from clinically normal-looking perilesional areas of East-Asian subjects: 1 biopsy sample was from a female arm (age 36 years, Fitzpatrick skin type III) and 5 samples were from a male thigh (age 46 years, Fitzpatrick skin type IV)
- After biopsy, 3 skin samples were treated with Resolve 532-nm handpiece (pulse duration 375 ps; fluence of 0.3 or 0.2 mJ/ μ beam) and 3 samples with Resolve 1064-nm handpiece (pulse duration 450 ps; fluence of 1.9 or 2.3 mJ/ μ beam)
- Samples were examined by a dermatopathologist for intra-epidermal, laser-induced optical breakdowns (LIOBs) and intra-dermal, laser-induced cavitations (LICs)

RESULTS

- Superficial, **intra-epidermal LIOBs were seen in skin treated with higher laser energies.**
- **Deep, intradermal LICs were seen in skin treated at lower energies**
- Lesions were spaced in 600- μ m intervals or its multiple
- Lesion sizes and depths were **consistent with previously reported values on Caucasian skin**



Successful treatment of ephelides in Asian skin using the picosecond 785-nm laser

Chung HJ, McGee JS, Lee SJ. J Cosmet Dermatol. 2019 Dec 20.

*785 nm Treatment
Pigmented Lesions*

CASE SERIES DETAILS

- 2 **Korean** females (age 29 and 25 years, Fitzpatrick skin type III) with **ephelides on the cheeks and/or nose** were treated
- Subjects received a single PicoWay 785-nm laser treatment with Fluence of 1.2 or 1.3 J/cm², pulse duration of 300 picoseconds, 3-mm spot size and 1-2 passes, until the end point of slight darkening of the ephelides was reached (without crust formation)

RESULTS

- Patients achieved **appreciable improvement to near complete clearance** of the ephelides without any complications
- **No post-inflammatory hyperpigmentation** observed

A 1064-nm Neodymium-doped Yttrium Aluminum Garnet Picosecond Laser for the Treatment of Hyperpigmented Scars

Koren A, Niv R, Cohen S, Artzi O. Dermatol Surg. 2019 May;45(5):725-729.

*Resolve 1064 nm Treatment
Hyperpigmented Scars*

Case Series Details

- 16 patients (6 males; 10 females, mean age 33.19 years, Fitzpatrick skin type II-VI) with stable non-improving hyperpigmented scars (scar age 18 months to 25 years) were treated
- 4.18 treatments on average (range 3-8), 3-6 weeks apart with the Resolve 1064 nm handpiece, at an energy level of 1.7 to 2.5 mJ/μbeam
- 2 independent dermatologists evaluated improvement at 6 months after the final treatment, using a global assessment scale (GAS) (1=0%-25%, poor improvement to 4=75%-100%, major change/excellent improvement)
- Mexameter quantitative evaluation of scar melanin content before and after laser treatments

RESULTS AT 6-MONTH FOLLOW-UP POST FINAL TREATMENT

- Mean GAS score was 3.31 ± 0.57
- Melanin content decreased by $39.11 \pm 11.58\%$ compared to pretreatment values
- Average subject satisfaction rate was high (2.6)
- Tolerance with treatment was good, and there were no significant side effects



Evaluation of the Safety and Efficacy of the Dual Wavelength Picosecond Laser for the Treatment of Benign Pigmented Lesions in Asians

Kung KY, Shek SY, Yeung CK, Chan HH. Lasers Surg Med. 2019 Jan;51:14-22.

*PicoWay 532 nm & 1064 nm HPs
Pigmented Lesions, including Melasma & CALMs*

STUDY DETAILS

- 12 female subjects (mean age 47.3 years, range 37-57; Fitzpatrick skin types III to IV) with benign pigmentary disorders underwent PicoWay treatments, while 11 subjects completed follow-ups
- PicoWay 532nm and 1064nm treatments at 2 to 6-week intervals
- Blinded evaluation of % clearance using clinical photography
- Follow-ups at 4, 8, and 12 weeks after the last treatment session

RESULTS

- **Over 90% of all pigments achieved good or excellent response (>50% lightening)** at both 1-month and 2-month follow-ups
- Clinical improvement was better for freckles and lentigines than melasma
- Lower rate of PIH induced by picosecond laser is explained by a much more targeted photomechanical and lesser photothermal effects than Q-switched laser

Q-switched double frequency Nd:YAG 532-nm nanosecond laser vs. double frequency Nd:YAG 532-nm picosecond laser for the treatment of solar lentigines in Asians

Vachiramon V, Iamsurang W, Triyankulsri K. Lasers Med Sci. 2018 Dec;33(9):1941-1947.

*PicoWay 532 nm HP
Lentigines*

STUDY DETAILS

- 30 subjects (1 male, 29 females, mean age 62 years, Fitzpatrick Skin Types III-IV) with at least 2 solar lentigines \geq 5-mm in diameter on the upper extremities were enrolled
- Paired lentigines were treated with PicoWay Zoom 532 nm handpiece (3 mm spot size, energy fluence of 0.3–0.9 J/cm² at 1 Hz) and 532 nm nanosecond laser (3 mm spot size, energy fluence of 1.4–1.7 J/cm²)
- Objective assessment was performed with a colorimeter to measure the luminance score (L*)
- 1 blinded dermatologist assessed degree of pigment clearance on a scale of 0 to 4: 0 = no improvement; 4 = excellent improvement (75–100%)

RESULTS AT 6 AND 12 WEEKS AFTER TREATMENT SERIES

- Both lasers showed significant improvement in mean L* from baseline ($p < 0.001$ for PicoWay)
- At the 12-week follow-up, 19 lesions (67.9%) treated with the PicoWay laser were rated as over 75% pigment clearance
- Patient satisfaction had a significantly higher score of 8.2 (visual analogue scale (VAS) with 0=Not satisfied to 10=Extremely satisfied) with PicoWay treatment compared to 7.1 with nanosecond laser treatment
- 2 lesions (7.1%) from each laser-treated group developed hyperpigmentation at the 12-week follow-up

Effects of a fractional picosecond 1,064 nm laser for the treatment of dermal and mixed type melasma

Chalermchai T, Rummaneethorn P. J Cosmet Laser Ther. 2018 Jun;20(3):134-139.

*Resolve 1064 nm Treatment
Melasma*

STUDY DETAILS

- 30 Thai females (mean age 47.5 years, Fitzpatrick Skin Type III or IV) with a confirmed diagnosis of dermal or mixed type melasma were enrolled
- Subjects were assigned by blocked randomization to receive 3 monthly treatments with the Resolve 1064 nm handpiece (fluence 1.3–1.5 mJ/μbeam; repetition rate 4 Hz; 2–3 passes until mild erythema occurred) plus daily application of 4% hydroquinone cream on one side of their face. On the contralateral side, subjects applied 4% hydroquinone cream daily
- Two independent, blinded dermatologists determined mMASI scores based on the clinical photographs at baseline compared to weeks 4, 8, and 12 after baseline

RESULTS AT WEEK 12 AFTER BASELINE

- PicoWay treatment with 4% hydroquinone cream resulted in a significantly better reduction in modified MASI score than 4% hydroquinone cream alone ($p = 0.035$)
- Adverse effects were limited to mild erythema, skin desquamation and a burning sensation, which all resolved spontaneously without intervention



Dual Wavelength Treatment Protocol with a Picosecond Laser for the Reduction of Facial Wrinkles

Gold MH. J Cosmet Laser Ther. 2018 Jun 8:1-5. doi: 10.1080/14764172.2018.1481514.

*Resolve Treatment
Wrinkles*

STUDY DETAILS

- 20 subjects (19 females; mean age 55±7 years, Fitzpatrick Skin Types II-IV) with bilateral facial wrinkling (mean Elastosis Score (ES) 5.7±0.9) in the perioral and periorbital regions
- 4 treatments at 1-month intervals with Resolve 1064nm handpiece (2 passes to full face with fluence of 2.3 mJ/μbeam) followed by 2 passes with the Resolve 532nm handpiece (fluence of 0.58 mJ/μbeam) to the full face
- 2 blinded dermatologists reviewed the digital clinical images and assigned a score for the full face, using the Fitzpatrick Wrinkle and Elastosis scale (1=mild elastosis to 9=severe elastosis) at 12 weeks after the 4th treatment

RESULTS AT 12-WEEK FOLLOW-UP AFTER 4TH TREATMENT

- Blinded assessment showed **75% of subjects had at least 1-point improvement**
- Blinded assessment correctly identified 75% (15/20) of the baseline images
- Investigator improvement rate was 100%, with a statistically significant **mean ES improvement of 2.1±0.8 points** compared to baseline assessment (p<0.001)
- Transient erythema and edema associated with treatment, resolving within several hours. 1 case of mild purpura and **no pigmentary changes, blistering or scarring**



A novel titanium sapphire picosecond-domain laser safely and effectively removes purple, blue, and green tattoo inks

Bernstein EF, Bhawalkar J, Schomacker KT. Lasers Surg Med. 2018 May 20.

785 nm Treatment
Green & Blue Tattoos

STUDY DETAILS

- 15 subjects (5 males, 10 females, skin phototypes II–IV, mean age 36 years) with 22 multi-color tattoos, containing **black** (n=15), **blue** (n=8), or **green** (n=13) tattoo ink
- 4 treatments at 6–10 week intervals with 785nm handpiece, 2-4 mm spot size, 3Hz repetition rate, mean 1.4, 2.6, 3.0 and 2.0 J/cm² for treatments 1-4, respectively
- 3 blinded physicians reviewed digital clinical images, using a 11-point scale (0=no clearance, to 10=100% or total clearance)

RESULTS AT 8-WEEK FOLLOW-UP AFTER 4TH TREATMENT

- Blinded assessment found 85%, **81%**, **74%**, 61%, 11%, and 5% clearance from baseline photos for purple, **blue**, **green**, black, red, and yellow pigments, respectively
- Typical erythema, edema and one case of pinpoint bleeding. **No hyper-, hypo-pigmentation or scarring**
- The 785nm laser wavelength has special affinity to purple, blue and green tattoo pigments
- In practice, the 1064nm wavelength would be used for black ink, while the 532nm laser would be reserved for yellow and red ink



Picosecond 532-nm neodymium-doped yttrium aluminum garnet laser-a promising modality for the management of verrucous epidermal nevi

Levi A, Amitai DB, Mimouni D, et al. Lasers Med Sci. 2018 Jan.

*PicoWay Treatment
Benign Pigmented Lesions*

STUDY DETAILS

- 6 subjects (3 males, 3 females) with skin phototypes I-II with verrucous epidermal nevus (VEN) on the body or face
- 4 of the 6 subjects had been unsuccessfully treated with laser and/or cryotherapy
- 2-6 PicoWay Zoom 532nm treatments, with spot size of 3 mm and fluence of 1.8 J/cm² (up to 3 passes) at 8 to 10-week intervals
- 2 blinded dermatologists assessed clinical images at 4 months after the final treatment, using a 5-point scale of 0 (exacerbation) to 4 (76-100% improvement)

RESULTS

- **100% of subjects demonstrated significant improvement** (mean $\pm 3.7 \pm 0.45$) on the 0-4 scale
- Treatments were well tolerated with minimal complications
- **100% subject satisfaction**
- No residual adverse effects or scarring



Treatment of acne scarring with a novel dual-wavelength, picosecond-domain laser incorporating a novel holographic beam-splitter

Bernstein E, Schomacker KT, Basilavecchio LD, et al. Lasers Surg Med. 2017 Nov;49(9):796-802.

*Resolve Treatment
Acne Scars*

STUDY DETAILS

- 19 subjects (3 males, 16 females) with mild-severe facial acne scars (rolling or boxcar), skin phototypes III-V and mean age 45 (range 23 to 70) years treated with Resolve 1064nm handpiece
- 8 subjects (1 male, 7 females) with skin phototypes III-IV and mean age 45 (range 23 to 65) years treated with Resolve 532 nm handpiece
- 4 monthly treatments
- 3 blinded physicians reviewed 81 digital clinical images, using a 10-point scale (1=10% improvement up to 10=100% improvement)

RESULTS

- Blinded assessment **correctly identified 75% of the baseline images**
- **81% of subjects showed improvement**
- **High patient satisfaction**
- Mild and transient erythema and edema associated with treatment, resolving within several hours
- **No hyper- or hypo-pigmentation or scarring**



Treatment of photoaging with a dual-wavelength, 532 nm and 1,064 nm picosecond-domain laser using a holographic optic

Bernstein E, Schomacker KT, Paranjape AS. J Drugs Dermatol. 2017 Nov 1;16(11):1077-1082.

*Resolve Treatment
Wrinkles*

STUDY DETAILS

- 14 subjects (2 males, 12 females) with mild-moderate wrinkles, skin phototypes I-IV and mean age 45 (range 23 to 70) years treated with Resolve 1064 nm handpiece
- 10 female subjects with skin phototypes II-IV and mean age 45 (range 23 to 65) years treated with Resolve 532 nm handpiece
- 5 treatments with 1064nm & 4 treatments with 532nm
- 3 blinded physicians reviewed 72 digital clinical images, using a 11-point scale (0=no improvement up to 10=100% improvement)

RESULTS

- Blinded assessment **correctly identified 72% of the baseline images**
- **86% of subjects treated with 1064nm** and 80% of subjects treated with 532nm were **satisfied to very satisfied** with outcome
- Mild and transient erythema and edema associated with treatment, resolving within several hours.
- **No hyper- or hypo-pigmentation or scarring**



Picosecond 532-nm neodymium-doped yttrium aluminum garnet laser - a novel and promising modality for the treatment of café-au-lait macules

Artzi O, Mehrabi JN, Koren A, et al. Lasers Med Sci. 2018 May;33(4):693-697.

*PicoWay 532 nm Treatment
CALMs*

STUDY DETAILS

- 16 subjects (5 males, 11 females) with skin phototypes II-IV and mean age 26 years with 1-3 café-au-lait macules (CALMs) present since birth
- 1-4 PicoWay Zoom 532 nm treatments, with spot size of 4–5 mm and fluence of 0.8–1.6 J/cm² at 4 to 8-week intervals
- Follow-up at 9 months after the final treatment
- 2 blinded dermatologists assessed clinical images, using a 6-point scale (0 = exacerbated to 5=complete (96–100%) clearance)

RESULTS

- 15 subjects evaluated at 9 months; 1 non-responder dropped from the study
- **All 15 patients demonstrated good to excellent improvement** (mean $\pm 3.76 \pm 0.94$) on the 0-5 scale
- Treatments were well tolerated with minimal complications
- Only two patients experienced partial recurrence
- **High subject satisfaction and comfort** associated with treatment



Laser treatment of professional tattoos with a 1064/532-nm dual-wavelength picosecond laser

Kauvar ANB, Keaney TC, Alster T. Dermatol Surg. 2017 Dec;43(12):1434-1440.

*PicoWay 532 & 1064 nm HPs
Tattoos*

STUDY DETAILS

- 60 subjects (23 males, 37 females) with skin phototypes I-VI and mean age 34±11years with 75 professional tattoos
- Up to 10 PicoWay Zoom 532/1064 nm treatments at 6-week intervals
- Blinded assessment of digital clinical images, using a 5-point scale (1=0-24%; 2=25-49%; 3=50-74%; 4=75-95%; 5≥95% clearance)

RESULTS

- Most of the tattoos contained black pigment with 40% having additional red, blue, green or other colored pigments
- **By blinded evaluator consensus, 86% of the treated tattoos** showed at least 50% clearance after 3 treatments (mean clearance score of 3.11)
- By investigator assessment, 70% of tattoos showed at least 75% clearance after 5 treatments
- Treatments were well tolerated with minimal complications
- **High subject satisfaction and comfort** associated with treatment

Picosecond 532 nm neodymium-doped yttrium aluminum garnet laser for the treatment of solar lentigines in darker skin types: safety and efficacy

Guss L, Goldman MP, Wu DC. Dermatol Surg. 2017 Mar;43(3):456-459.


*PicoWay 532 nm Treatment
Benign Pigmented Lesions*

CASE STUDY DETAILS

- 255 discrete pigmentary lesions in 6 Skin Type IV patients (3 women and 3 men) underwent a single treatment with the 532 nm PicoWay Zoom handpiece
- **78% of lesions (201/255) had 75-100% clearance after 1 treatment**
- 2 lentigines (0.8%) worsened because of PIH, both in a patient who admitted to picking the treated area.
- No other cases of PIH or adverse events

TABLE 1. Patient Demographics

Sex	Skin Type	Ethnicity	Age
M	IV	Hispanic	19
M	IV	Chinese	32
F	IV	Chinese	20
F	IV	Hispanic	54
M	IV	Korean	33
F	IV	Vietnamese	30





Successful treatment of a red and black professional tattoo in skin type VI with a picosecond dual-wavelength, neodymium-doped yttrium aluminum garnet laser

Friedman DJ. Dermatol Surg. 2016 Sep;42(9):1121-3.

*PicoWay Treatment
Tattoos*

CASE STUDY DETAILS

- A 29-year-old female (of Ethiopian lineage) with Fitzpatrick skin Type VI was treated for a 9-year-old professional black and red tattoo on the neck
- 3 treatments at 3-week intervals with PicoWay Zoom 1064 nm (black tattoo) and PicoWay Zoom 532 nm (red tattoo) with large spot sizes
- Mild and transient localized edema and erythema in the treatment area immediately after the procedure, which resolved within 24 hours
- No adverse events
- 90% clearance for the red ink and ~75% clearance for the black ink



Figure 1. A 29-year-old woman with Fitzpatrick skin Type VI and a professional black and red tattoo on the neck.



Figure 2. Clinical response was approximately 75% clearance for the black ink and 90% clearance for the red ink, after 3 treatments performed over 1.5 months.



A novel dual-wavelength, Nd:YAG, picosecond-domain laser safely and effectively removes multicolor tattoos

Bernstein EF, Schomacker KT, Basilavecchio LD, et al. Lasers Surg Med. 2015 July.

*PicoWay Treatment
Tattoos*

STUDY DETAILS

- 21 subjects (Fitzpatrick Skin Type I-IV) with 31 tattoos (black or multi-colored green, blue, purple, red, and yellow)
- Up to 7 treatments with PicoWay Zoom 532 nm/1064 nm handpieces, at 6 to 10-week intervals
- 3-5 mm spot size, 1.4 - 5.3 J/cm² fluence with 1064nm wavelength (Black, blue, green, and purple inks), 0.4 to 2.1 J/cm² fluence with 532nm wavelength (red and yellow inks)
- Blinded assessment of photos, using 10-point scale (0=no improvement to 10=100% or total clearance)

RESULTS

- Mean score for **blinded evaluation: 7.94±0.09** - corresponding to **79% removal** after an average of 6.5 treatments
- Average **92% clearance of black ink** after an average of 6.5 treatments
- Average **80% clearance of red ink** after an average of 4.5 treatments
- **No scarring, or moderate or severe pigmentary alterations** were seen in the 3-month follow-up cross-polarized images



Thank you

Disclaimer: All contents of this material are for informational purposes only and provided by Candela without warranties of any kind. Healthcare professionals are solely responsible for making their own independent evaluation as to the suitability of any product for any particular purpose and in accordance with country specific regulations. The availability of products and the indications mentioned in this material are subject to the regulatory requirements and product registration status in each country. Refer to the User Manual for country specific indications. Products and technical specifications may change without notice. Please contact Candela for more details.

© 2025 Candela Corporation. This material contains registered and unregistered trademarks, trade-names, service marks and brand names of Candela Corporation and its affiliates. All other trademarks are the property of their respective owners. All rights reserved. CLI103659EN-NA, Rev. 101